All In Biotech

Drug Trial Radar · NCT04652102

A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older

COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older

Last checked: Nov 19, 2026Latest source record: Apr 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 39,680 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

39,680

Actual

Start

Dec 11, 2020

Primary completion

Jun 10, 2022

Study completion Jun 10, 2022

Sponsor

Lead sponsor
CureVacIndustry
Sponsor type
Industry
First posted
Dec 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the randomized observer-blinded phase 2b/3 part of this trial is to demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19 of any severity in SARS-CoV-2 naïve participants.

Conditions

  • Covid19
  • SARS-CoV-2

Interventions

  • CVnCoVBiological

    Intramuscular (IM) injection.

  • PlaceboBiological

    Intramuscular (IM) injection.

  • Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination programBiological

    Intramuscular (IM) injection will be received as standard of care (SoC) outside the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced a First Episode of Virologically-confirmed {Reverse Transcription Polymerase Chain Reaction (RT-PCR) Positive} Case of COVID-19 of Any SeverityTime frame: Day 44 to Day 393
  2. Number of Participants Who Experienced One or More Medically-attended Adverse Events (AE)Time frame: Day 1 to Day 211
  3. Number of Participants Who Experienced One or More Serious AE (SAE)Time frame: Day 1 to Day 393
  4. Intensity of SAEs as Per Investigator AssessmentTime frame: Day 1 to Day 393
  5. Number of Participants Who Experienced One or More Adverse Event of Special Interest (AESI)Time frame: Day 1 to Day 393
  6. Number of Participants Who Experienced a Fatal SAETime frame: Day 1 to Day 393
  7. Phase 2b Participants Only: Number of Participants Who Experienced One or More Solicited AETime frame: Up to 7 days after vaccination (Days 1 to 7 and Days 29 to 36)
  8. Phase 2b Participants Only: Intensity of Solicited AEs as Per Investigator AssessmentTime frame: Up to 7 days after vaccination (Days 1 to 7 and Days 29 to 36)
  9. Phase 2b Participants Only: Duration of Solicited AEsTime frame: Up to 7 days after vaccination (Days 1 to 7 and Days 29 to 36)
  10. Phase 2b Participants Only: Number of Participants Who Experienced One or More Unsolicited AETime frame: Up to 28 days after vaccination (Days 1 to 29 and Days 29 to 57)
  11. Phase 2b Participants Only: Intensity of Unsolicited AEs as Per Investigator AssessmentTime frame: Up to 28 days after vaccination (Days 1 to 29 and Days 29 to 57)
  12. Number of Participants Who Experienced One or More AEs Leading to Vaccine Withdrawal or Trial DiscontinuationTime frame: Day 1 to Day 393

Locations

46 sites in 10 countries. Site status is shown where the registry gives one.

  • Instituto de Investigaciones Clinicas Quilmes

    Buenos Aires, Argentina

  • Hospital Interzonal General Agudos Prof. Dr. Ramon Carrillo

    Buenos Aires, Argentina

  • Hospital Interzonal General de Agudos Vicente Lopez y Planes

    Buenos Aires, Argentina

  • Hospital Zonal General de Agudos Descentralizado Evita Pueblo de Berazategui

    Buenos Aires, Argentina

  • Fundación Cenit Para La Investigación En Neurociencias

    Buenos Aires, Argentina

  • Instituto de Investigaciones Clínicas Mar del Plata

    Mar del Plata, Argentina

  • Sanatorio Parque

    Rosario, Argentina

  • Corporación Médica Sanatorio

    San Martin, Argentina

  • Instituto De Investigaciones Clinica Zarate

    Zárate, Argentina

  • Cohezio - Bruxelles

    Brussels, Belgium

  • Mensura

    Brussels, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Clínica de la Costa

    Barranquilla, Colombia

  • CAIMED - Bogota Clinical Research Center

    Bogotá, Colombia

  • Centro de Estudios en Infectología Pediátrica (CEIP)

    Cali, Colombia

  • Fundacion Dominicana de Perinatologia Pro Bebe

    Santo Domingo, Dominican Republic

  • Instituto Dermatológico Dominicano y Cirugía de Piel Dr. Huberto Bogaert Díaz

    Santo Domingo, Dominican Republic

  • Clínica Cruz Jiminian

    Santo Domingo, Dominican Republic

  • Hospital General Regional Marcelino Vélez Santana

    Santo Domingo, Dominican Republic

  • Uniklinik Köln

    Cologne, Germany

  • Ludwig-Maximilians-Universität München

    München, Germany

  • Universitätsklinikum Tübingen - Institut für Tropenmedizin, Reisemedizin und Humanparasitologie

    Tübingen, Germany

  • Panamerican Clinical research Mexico (Guadalajara)

    Guadalajara, Mexico

  • Panamerican Clinical Research Mexico S.A. DE C.V.

    Juriquilla, Mexico

  • Instituto Nacional De Ciencias Medicas Y Nutricion Salvador Zubiran

    Mexico City, Mexico

  • CAIMED - México

    Mexico City, Mexico

  • Unidad de Medicina Especializada SMA

    San Juan del Río, Mexico

  • Centro Medico Zambrano Hellion TecSalud

    San Pedro Garza García, Mexico

  • Noordwest Ziekenhuisgroep

    Alkmaar, Netherlands

  • Amsterdam Universitair Medische Centra - Academisch Medisch Centrum

    Amsterdam, Netherlands

  • The Julius Center - Utrecht Science Park - Stratenum

    Utrecht, Netherlands

  • Centro De Vacunacion Internacional - CEVAXIN Chorreras

    Panama City, Panama

  • Instituto de Investigaciones Científicas y Servicios de Alta Tecnología

    Panama City, Panama

  • Centro De Vacunacion Internacional - CEVAXIN 24 Diciembre

    Panama City, Panama

  • Centro de Vacunacion Internacional - CEVAXIN Avenida Mexico

    Panama City, Panama

  • Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales

    Callao, Peru

  • Hospital de Chancay y Servicios básicos de Salud

    Chancay, Peru

  • Clinica Medica San Martin

    Ica, Peru

  • Instituto de Investigación Nutricional - Las Gardenias

    Lima, Peru

  • Instituto de Investigación Nutricional - San Carlos

    Lima, Peru

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.